An interventional study of Propofol and Rocuronium in Kidney Failure, Acute, Myopathy; Drugs and Heart Arrhythmia, sponsored by 4th Military Clinical Hospital with Polyclinic, Poland. Recruiting at 1 site in Poland. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-11-27.
Sponsored by 4th Military Clinical Hospital with Polyclinic, Poland · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Acute Kidney Injury with a site in Poland — 5 open to participants now, 5 under way, none of them phase 3. Acute Kidney Injury · Poland.
Among the 25 studies in Acute Kidney Injury with a site in Poland, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is one of 8 with no phase, and was the 22nd registered.
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
Browse Acute Kidney Injury studies →5 of the 25 studies in Acute Kidney Injury with a site in Poland are open now. Recruiting first, the newest first:
Collegium Medicum w Bydgoszczy · Sites in Poland
Ages 18+
3ive Labs · Sites in Poland, United States
Ages 22–85
Uniwersytecki Szpital Kliniczny w Opolu · Sites in Poland
Ages 18+
Medical University of Gdansk · Sites in Poland
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 32 is below the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Median enrollment 50 across the 11 interventional studies, 82 across the 14 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 25 have an industry lead sponsor. The 10 most frequent:
4th Military Clinical Hospital with Polyclinic, Poland is the lead sponsor of 10 studies on the registry; 8 are open to participants now.
4th Military Clinical Hospital with Polyclinic, Poland has 1 study filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
1 of the studies in Acute Kidney Injury with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT070179333ive LabsGroundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies in Acute Kidney Injury with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study aims to improve the safety of the electroporation ablation (PFA) procedure by using muscle relaxants to reduce skeletal muscle damage during the procedure. It will also assess myocardial damage to improve the procedure's quality and speed up recovery after the procedure.
The procedure of electroporation (PFA) is a method of atrial fibrillation ablation introduced in Poland in 2022. A biphasic high voltage current (2000 volts) is applied to the electrode placement site. Local coagulation of the site is followed by myocardial scarring and interruption of the pathological conduction pathway of premature electrical impulses in the heart. The patient, once qualified by the cardiologist for the procedure of electroporation ablation (PFA), will undergo a standard anaesthetic qualification process with assessment of basic demographics, comorbid conditions, medications taken, determination on the surgical risk scale.
Participants will be randomized into 2 groups. Group I will consist of patients undergoing general anaesthesia without the muscle relaxant rocuronium. Group II will consist of patients undergoing general anaesthesia with the muscle relaxant rocuronium. A total of 32 patients were initially planned for the study (16 patients in each of the two groups). Before the procedure, the anaesthetist will be given a sealed envelope by a person unrelated to the project (hospital administration staff) with a randomised method of anaesthesia based on simple randomisation. Before the procedure, each patient will have a transthoracic ultrasound of the heart (TTE). The patient will not know which study group he/she has been assigned to. The operator performing the procedure will not be informed about the type of anaesthesia used [double blind randomisation].
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group I - 16 patients undergoing general anaesthesia with endotracheal intubation, during the induction of anaesthesia, the patients will be administered a muscle relaxant from the depolarising group (Chlorsuccilin®) for the endotracheal intubation procedure (using precurarisation). This is a method of pharmacologically preventing the muscle fasciculations characteristic of depolarising agents. For this purpose, a low-dose muscle relaxant from the non-depolarising group - (rocuronium, Esmeron®) will be administered just before the actual dose of the depolarising agent. No muscle relaxant will be used during the actual procedure, but the level of muscle relaxation will be continuously monitored through the use of the NMT - TOF % technique (a method of measuring neuromuscular excitability that allows real-time assessment of muscle strength).
Drug: Propofol
Group II -16 patients undergoing general anaesthesia with endotracheal intubation, during the induction of anaesthesia the patients will be administered a muscle relaxant from the depolarising group (rocuronium, Esmeron®) for the endotracheal intubation procedure (using precurarisation). This is a method of pharmacological prevention of muscle fasciculation, characteristic of depolarising agents. For this purpose, a low-dose muscle relaxant from the non-depolarising group (rocuronium, Esmeron®) will be administered just before the actual dose of the depolarising agent. During the procedure itself, the level of relaxation will be continuously monitored by using the NMT - TOF % technique (a method of measuring neuromuscular excitability that allows real-time assessment of muscle strength). During the ablation performed, the patient will be under the influence of a muscle relaxant from the non-depolarising group (rocuronium, Esmeron®).
Drug: Rocuronium
Induction of anaesthesia: * Fentanyl 1-3ug/kg/m.c i.v. * Ketamine 50mg i.v. * Propofol 1.5-2mg/kg/m.c i.v. * Rocuronium 5mg (b.w.\<60kg) 10mg (b.w.\>60kg) i.v. Precurarisation * Chlorucinylcholine 1-1.5mg/kg/m.c i.v. -\> Intubation Application (cycle of 5 pulses with 2000V biphasic alternating current) - during PFA: - In case of ventilatory distress pPeak \>30 cm H2O ad hoc Propofol 0.25-0.75mg/kg/m.c i.v. Elimination of neuromuscular blockade: - To exclude residual relaxation after pre-curative: 1mg Atropine i.v. + 0.5mg Neostigmine i.v.
Also known as: no muscular relaxant, general anaesthesia
Induction of anaesthesia: * Fentanyl 1-3ug/kg/m.c i.v. * Ketamine 50mg i.v. * Propofol 1.5-2mg/kg/m.c i.v. * Rocuronium 5mg (b.w.\<60kg) 10mg (b.w.\>60kg) i.v. Precurarisation * Chlorucinylcholine 1-1.5mg/kg/m.c i.v. -\> Intubation Application (cycle of 5 pulses with 2000V biphasic alternating current) - during PFA: - rocuronium 0.1-0.3mg/kg/m.c i.v. For TOF \<2 Abolition of neuromuscular blockade: - Atropine 1-1.5mg i.v. + 1-3mg Neostigmine i.v. Or Sugammadex 2-4mg/kg/m.c i.v.
Also known as: muscular relaxant, general anaesthesia
Baseline laboratory parameters and additional tests
Serum creatinine Serum potassium General morphology evaluation of HGB and PLT values Assessment of QoR-15 Measurement of heart size and mass on TTE ultrasound
Time frame: up to 24 hours before procedure
During the procedure (before the start of current application)
Serum myoglobin Serum troponin Serum CPK
Time frame: before the start of current application
Endline laboratory parameters and additional tests
Serum myoglobin Serum troponin Serum CPK Serum creatinine Serum potassium Total morphology evaluation of HGB and PLT values
Time frame: 12 hours after procedure
NRS
numerical pain scale 0-10 points
Time frame: Checked before procedure and every 6 hours for the first 24 hours after the procedure
QoR - 15
post-operative quality of life and improvement scale 0-150 points
Time frame: Administered to the patient before surgery and 24 hours after surgery
BMI
Body mass index 15-45
Time frame: Before performing procedure
Started Aug 2024 (actual). Primary completion is estimated for Dec 2025, 16 months after the start.
Of 251 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 16 months is below that.
Counting every sponsor, half of 269 studies reached it within 26 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Propofol · Rocuronium
4th Military Clinical Hospital with Polyclinic, Poland